Companies › GRIN Therapeutics
1 active drug program in 5 registered trials: 4 Phase 1, 1 Phase 3; Neurology, Gastroenterology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Radiprodil Glutamate NMDA receptor; GRIN1/GRIN2B antagonist | GRIN1, GRIN2B | Phase 3 | GRIN-related Neurodevelopmental Disorder; Healthy Adult Participants; GRIN-related Disorders; Hepatic Impairment … | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07884734 | Radiprodil | Phase 1 | Healthy Adult Participants | Other | Oct 2026 |
| NCT05818943 | Radiprodil | Phase 1 | GRIN-related Disorders | Neurology | Nov 2026 |
| NCT07224581 | Radiprodil | Phase 3 | GRIN-related Neurodevelopmental Disorder | Other | May 2027 |
| NCT07457229 | Radiprodil | Phase 1 | Hepatic Impairment | Gastroenterology | May 2027 |
| NCT06392009 | Radiprodil | Phase 1 | Tuberous Sclerosis Complex | Other | Jun 2028 |
Neuren Pharmaceuticals Aptinyx SHINKEI Therapeutics Syndeio Biosciences Dr. F. Köhler Chemie
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.